Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis
Status:
Active, not recruiting
Trial end date:
2023-12-13
Target enrollment:
Participant gender:
Summary
To evaluate the effect of denosumab on lumbar spine bone mineral density (BMD) Z-score as
assessed by dual-energy X-ray absorptiometry (DXA) at 12 months in children 5 to 17 year of
age with Glucocorticoid (GC)-induced osteoporosis (GiOP).